Evidence map›Paper›PMID 27825138›Full record

SynthesisOncotarget2016

Heme oxygenase-1 gene promoter polymorphisms are associated with coronary heart disease and restenosis after percutaneous coronary intervention: a meta-analysis.

Ming-Ming Zhang, Ying-Ying Zheng, Ying Gao, Jing-Zhan Zhang, Fen Liu, Yi-Ning Yang, Xiao-Mei Li, Yi-Tong Ma, Xiang Xie

Open access · diamondAbstract readMeta-AnalysisReview
In one paragraph

Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Role ofInternational journal of molecular sciences · 2021
    Article
  7. Review
  8. Article
  9. Royal Society open science · 2020
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ming-Ming ZhangDepartment of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471000, China.
Ying-Ying ZhengHeart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China.
Ying GaoDepartment of Cadre ward, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China.
Jing-Zhan ZhangHeart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China.
Fen LiuHeart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China.
Yi-Ning YangHeart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China.
Xiao-Mei LiHeart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China.
Yi-Tong MaHeart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China.
Xiang XieHeart Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China.
Xinjiang Medical University · CNFirst Affiliated Hospital of Xinjiang Medical University · CNLuoyang Central Hospital Affiliated to Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous published studies have suggested that there is association between heme oxygenase-1 (HO-1) gene polymorphisms and coronary heart disease (CHD) or restenosis (RS) after percutaneous coronary intervention (PCI). This study aimed to clarify this association using a meta-analysis method. We used a systematic search for studies on the association of HO-1gene polymorphisms with CHD or RS in PubMed, Web of Science, the Cochrane Library, Wanfang Data and CNKI (China National Knowledge Infrastructure). We used Stata 12.0 software to perform the meta-analyses. Twenty-three studies, involving 12,130 patients with CHD or RS and 14,181 controls, were included. A statistically significant association between the HO-1(GT)n repeat length polymorphism and CHD was observed under allelic (odds ratio (OR) = 0.929, 95% confidence interval (CI) = 0.881-0.978, p= 0.005), recessive (OR = 0.858, 95%CI = 0.780-0.945, p= 0.002), and co-dominant (OR = 0.843, 95%CI = 0.754-0.942, p= 0.003) models. Moreover, we also found a statistically significant association between the HO-1(GT)n repeat length polymorphism and RS under allelic (OR = 0.718, 95%CI = 0.541-0.953, p= 0.022) and co-dominant (OR = 0.522, 95%CI = 0.306-0.889, p=0.017) models. We found a significant association of the HO-1T(-413)A single-nucleotide polymorphism (SNP) with CHD under allelic (OR = 0.915, 95%CI = 0.842-0.995, p= 0.038), recessive (OR = 0.869, 95%CI = 0.760-0.994, p= 0.041), and co-dominant (OR = 0.792, 95%CI = 0.663-0.946, p=0.010) models. Our study indicates that both the HO-1(GT)n repeat length polymorphism and the T(-413)A SNP are associated with decreased risk of CHD. The (GT)n repeat length polymorphism was associated with RS following PCI.

Indexed as

Polymorphism, Single NucleotidePromoter Regions, GeneticAdultAgedCase-Control StudiesChi-Square DistributionCoronary DiseaseCoronary RestenosisFemaleGene FrequencyGenetic Association StudiesGenetic Predisposition to DiseaseHeme Oxygenase-1HumansMaleMiddle AgedHeme Oxygenase-1HMOX1 protein, humancoronary heart diseaseheme oxygenase-1 genemeta-analysispolymorphismrestenosis

Identifiers

PMID27825138
PMCPMC5347780
OpenAlexW2547666779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.